HER2 overexpression and amplification in urothelial carcinoma of the bladder is associated with MYC coamplification in a subset of cases

American Journal of Clinical Pathology

Volumn 130, Issue 2, 2008, Pages 274-281

  Hansel, Donna E ^a,b   Swain, Eric ^a   Dreicer, Robert ^a,b   Tubbs, Raymond R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

Bladder; ERBB2; Fluorescence in situ hybridization; Gene amplification; HER2; Immunohistochemistry; Metastasis; MYC

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADVANCED CANCER; ARTICLE; CANCER INVASION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METASTASIS; ONCOGENE MYC; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UROGENITAL TRACT TUMOR;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENES, ERBB-2; GENES, MYC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; URINARY BLADDER NEOPLASMS;

EID: 48649083362     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/41VLTFX3YPP1HF6F     Document Type: Article

References (35)

1. Meric-Bernstam F, Hung MC. Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin Cancer Res. 2006;12:6326-6330.
2. Rabindran SK. Antitumor activity of HER-2 inhibitors. Cancer Lett. 2005;227:9-23.
3. Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39-51.
4. Hynes NE, Lane HA. Myc and mammary cancer: Myc is a downstream effector of the ErbB2 receptor tyrosine kinase. J Mammary Gland Biol Neoplasia. 2001;6:141-150.
5. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(suppl 4):S3-S8.
6. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer. 2005;6:240-246.
7. Coogan CL, Estrada CR, Kapur S, et al. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology. 2004;63:786-790.
8. Gardmark T, Wester K, De la Torre M, et al. Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int. 2005;95:982-986.
9. Hauser-Kronberger C, Peham K, Grall J, et al. Novel approach of human epidermal growth factor receptor 2 detection in noninvasive and invasive transitional cell carcinoma of the bladder. J Urol. 2006;175:875-880.
10. Kruger S, Lange I, Kausch I, et al. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and p53 in minimally invasive urothelial carcinoma of the urinary bladder: a multitissue array study with prognostic implications. Anticancer Res. 2005;25:263-271.
11. de Pinieux G, Colin D, Vincent-Salomon A, et al. Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch. 2004;444:415-419.
12. Sato K, Moriyama M, Mori S, et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer. 1992;70:2493-2498.
13. Kruger S, Weitsch G, Buttner H, et al. Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol. 2002;21:981-987.
14. Kruger S, Weitsch G, Buttner H, et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer. 2002;102:514-518.
15. Gandour-Edwards R, Lara PN Jr, Folkins AK, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer. 2002;95:1009-1015.
16. Latif Z, Watters AD, Dunn I, et al. HER2 overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder. Br J Cancer. 2003;89:1305-1309.
17. Park K, Kwak K, Kim J, et al. MYC amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. Hum Pathol. 2005;36:634-639.
18. Simon R, Atefy R, Wagner U, et al. HER-2 and TOP2A coamplification in urinary bladder cancer. Int J Cancer. 2003;107:764-772.
19. Kim C, Bryant J, Horne Z, et al. Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC in vivo [abstract]. Breast Cancer Res Treat. 2005;94:S6.
20. Sauter G, Carroll P, Moch H, et al. MYC copy number gains in bladder cancer detected by fluorescence in situ hybridization. Am J Pathol. 1995;146:1131-1139.
21. Zaharieva B, Simon R, Ruiz C, et al. High-throughput tissue microarray analysis of CMYC amplification in urinary bladder cancer. Int J Cancer. 2005;117:952-956.
22. Garcia JA, Dreicer R. Systemic chemotherapy for advanced bladder cancer: update and controversies. J Clin Oncol. 2006;24:5545-5551.
23. Greene FL, Page DL, Fleming ID, et al; for the American Joint Committee on Cancer, eds. Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
24. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. 1990;5:953-962.
25. Taylor SL, Platt-Higgins A, Rudland PS, et al. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer. 1998;76:459-463.
26. Tubbs RR, Hicks DG, Cook J, et al. Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 status in adenocarcinoma of the breast: a single institution experience. Diagn Mol Pathol. 2007;16:207-210.
27. Mitsui F, Dobashi Y, Imoto I, et al. Non-incidental coamplification of Myc and ERBB2, and Myc and EGFR, in gastric adenocarcinomas. Mod Pathol. 2007;20:622-631.
28. Chakravarti A, Winter K, Wu CL, et al. Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys. 2005;62:309-317.
29. Wang S-C, Lien H-C, Xia W, et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. Cancer Cell. 2004;6:251-261.
30. Peyromaure M, Scotte F, Amsellem-Ouazana D, et al. Trastuzumab (Herceptin) in metastatic transitional cell carcinoma of the urinary tract: report on six patients. Eur Urol. 2005;48:771-778.
31. Salzberg M, Borner M, Bauer J-A, et al. Trastuzumab (Herceptin) in patients with HER-2-overexpressing metastatic or locally advanced transitional cell carcinoma of the bladder: report on 7 patients [letter]. Eur J Cancer. 2006;42:2660-2661.
32. Hussain MHA, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25:2218-2224.
33. Watters AD, Latif Z, Forsyth A, et al. Genetic aberrations of MYC and CCND1 in the development of invasive bladder cancer. Br J Cancer. 2002;87:654-658.
34. Onodera T, Hashimoto Y, Yagihashi S. MYC, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma. Pathol Int. 1997;47:209-216.
35. Christoph F, Schmidt B, Schmitz-Drager BJ, et al. Overexpression and amplification of the MYC gene in human urothelial carcinoma. Int J Cancer. 1999;84:169-173.